Mechanism of Activation of Anti-HCMV Nucleoside Analog MBX 2168
PublicDownloadable Content
open in viewerHuman Cytomegalovirus (HCMV) infection can progress into a persistent and life-threatening disease in infants and immune-compromised individuals, especially when resistant to available antiviral therapies. The purpose of this project was to study two proposed cellular activation pathways of antiviral drug MBX 2168, a nucleoside analog that inhibits viral DNA replication. This project specifically examined the de-alkylation of MBX 2168 monophosphate (upper pathway) and mono-phosphorylation of synguanol by viral-encoded kinase UL97 (lower pathway). The results indicate that both pathways theoretically participate in drug activation, but the cell prefers the upper pathway for MBX 2168 activation.
- This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.
- Creator
- Contributors
- Publisher
- Identifier
- E-project-042914-151020
- Advisor
- Year
- 2014
- Sponsor
- Date created
- 2014-04-29
- Resource type
- Major
- Rights statement
- Last modified
- 2023-09-20
Relations
- In Collection:
Items
Items
Thumbnail | Title | Visibility | Embargo Release Date | Actions |
---|---|---|---|---|
Brittany_Jones,_MQP_Final.pdf | Public | Download |
Permanent link to this page: https://digital.wpi.edu/show/g445cf640